Roche receives Swissmedic approval for eye syringe
Published: Monday, Dec 16th 2024, 08:40
Back to Live Feed
The pharmaceutical company Roche has now also received approval in Switzerland for its ophthalmic drug Vabysmo in a prefilled syringe for the treatment of three retinal diseases. After the EU Commission gave the green light on Friday, the Swiss Agency for Therapeutic Products (Swissmedic) has now also granted approval.
As Roche wrote on Friday, the single-dose prefilled syringe is currently the only practical alternative to the otherwise available Vabysmo vials. It can be used to treat neovascular or "wet" age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). All three can lead to loss of vision if left untreated.
The ready-to-use syringe is packaged together with a specific needle especially for intravitreal injection - in other words, it can be injected into the vitreous body of the eye as it is - and offers ophthalmologists a convenient way to administer this treatment, according to the announcement on Friday. More than nine million people in the EU are affected by these diseases.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic